ArticleACS omega2025
Zinc Phosphate Microparticles against Nosocomial and Oral Bacteria: Synthesis, Analytical Characterization, and Biocompatibility.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sustainable ZnO/ZnGels (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nosocomial bacteria represent a significant global health problem. In addition, oral pathogens causing oral infections, such as periodontitis and peri-implantitis, are the main cause of the failure of oral implant treatments, mainly due to bacterial resistance related to the indiscriminate use of antibiotics in recent years. Therefore, identifying antimicrobial and biocompatible agents, such as some zinc-derived compounds, represents a promising alternative to the development of new antibacterial biomaterials. In this study, zinc phosphate microparticles were synthesized by chemical precipitation and characterized by FTIR, DLS, TEM, XRD, and XPS. Their antibacterial effect was evaluated against nosocomial and oral bacteria, while their biocompatibility was assessed using human fibroblasts and osteoblasts. The results showed zinc phosphate microparticles with elongated morphologies, a hopeite crystal structure with an average crystallite size of about 35 nm, a hydrodynamic diameter of approximately 4.8 μm, and a ζ-potential close to neutrality. Regarding the antibacterial properties, zinc phosphate microparticles showed high antibacterial activity against the eight different bacterial species evaluated. In almost all species, an inhibition percentage close to 100% was observed, depending on the concentration, while in the biocompatibility tests, particle concentrations between 0.05 and 0.4 mg/mL were not cytotoxic to either of the eukaryotic cell types evaluated. These findings suggest that zinc phosphate microparticles synthesized by chemical precipitation possess antibacterial properties against pathogens associated with nosocomial and oral infections and exhibit biocompatibility with human fibroblasts and osteoblasts. Therefore, zinc phosphate microparticles have the potential for diverse applications in the medical and dental fields due to their antibacterial properties and biocompatibility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.